{"issuance_frequency":"","notes_translated":{"fr":"Le présent document fournit des directives sur l'étude et l'analyse des différences liées au sexe dans les essais cliniques relatifs aux produits thérapeutiques. ","en":"This document provides guidance on the study and analysis of sex differences in clinical trials of therapeutic products in order to generate evidence to advise on the optimal use of therapeutic products in both women and men. "},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"c3a81b7a-2617-4650-b717-3ce60bd24f5e","metadata_created":"2021-06-02T18:42:12.706575","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-06-02T18:42:12.706582","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-02","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["document d'orientation","inclusion des femmes","inclusion des femmes dans les essais cliniques","analyse des différences entre les sexes","différences entre les sexes dans les essais cliniques","produits thérapeutiques","utilisation optimale des produits thérapeutiques"],"en":["guidance document","inclusion of women","inclusion of women in clinical trials","analysis of sex differences","sex differences in clinical trials","therapeutic products","optimal use of therapeutic products"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Document d'orientation : Considérations relatives à l'inclusion des femmes dans les essais cliniques et à l'analyse des données selon le sexe","en":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"c3a81b7a-2617-4650-b717-3ce60bd24f5e","datastore_active":false,"id":"476f6d8e-c16e-4a59-8999-4d8e8dc56680","character_set":"","state":"active","name_translated":{"fr":"Document d'orientation : Considérations relatives à l'inclusion des femmes dans les essais cliniques et à l'analyse des données selon le sexe","en":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences","language":["en"],"created":"2021-06-02T18:42:12.810015","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/clinical-trials/considerations-inclusion-women-clinical-trials-analysis-data-sex-differences.html#a11","last_modified":null,"position":0,"revision_id":"328cebc7-fb8d-433c-af88-2671c4583195","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"c3a81b7a-2617-4650-b717-3ce60bd24f5e","datastore_active":false,"id":"d27aba09-ca54-4361-9276-35fd0a5bfe16","character_set":"","state":"active","name_translated":{"fr":"Document d'orientation : Considérations relatives à l'inclusion des femmes dans les essais cliniques et à l'analyse des données selon le sexe","en":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences","language":["fr"],"created":"2021-06-02T18:42:12.810021","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/essais-cliniques/considerations-relatives-inclusion-femmes-essais-cliniques-analyse-donnees-selon-sexe-document-orientation.html#a11","last_modified":null,"position":1,"revision_id":"328cebc7-fb8d-433c-af88-2671c4583195","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2013-12-10 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"c3a81b7a-2617-4650-b717-3ce60bd24f5e","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This document provides guidance on the study and analysis of sex differences in clinical trials of therapeutic products in order to generate evidence to advise on the optimal use of therapeutic products in both women and men. ","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences","revision_id":"328cebc7-fb8d-433c-af88-2671c4583195"}